BACKGROUND AND OBJECTIVES: Follistatin mediates muscle growth and bone mineralization. At present, it is unknown whether circulating follistatin levels are altered in chronic kidney disease (CKD) or links to CKD risk factors and outcomes. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Plasma follistatin levels were cross-sectionally analyzed in relation to protein-energy wasting (PEW), handgrip strength (HGS), bone mineral density (BMD), and inflammatory markers in 280 CKD stage 5 patients, 32 CKD stage 4 patients, 16 CKD stage 3 patients, and 32 control subjects. In CKD stage 5 patients survival was prospectively investigated during a follow-up period of up to 5 years. RESULTS: The plasma follistatin concentration was not higher in CKD stage 5 patients than in other CKD stages or controls. In CKD stage 5 patients, circulating follistatin positively correlated with age, high-sensitivity C-reactive protein (hsCRP), and IL-6; negatively correlated with HGS, serum creatinine, and BMD; and was increased in patients with PEW. In a multivariate logistic regression model, lower HGS, lower BMD, and higher hsCRP independently correlated with higher follistatin levels. In a Cox regression model, follistatin levels were not associated with all-cause mortality. CONCLUSIONS: Circulating follistatin levels were neither elevated nor predicted outcome in patients with CKD. However, increased follistatin levels occurred together with increased inflammation, reduced muscle strength, and low BMD, suggesting an involvement of a mechanism including follistatin in the uremic wasting process.
BACKGROUND AND OBJECTIVES: Follistatin mediates muscle growth and bone mineralization. At present, it is unknown whether circulating follistatin levels are altered in chronic kidney disease (CKD) or links to CKD risk factors and outcomes. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Plasma follistatin levels were cross-sectionally analyzed in relation to protein-energy wasting (PEW), handgrip strength (HGS), bone mineral density (BMD), and inflammatory markers in 280 CKD stage 5 patients, 32 CKD stage 4 patients, 16 CKD stage 3 patients, and 32 control subjects. In CKD stage 5 patients survival was prospectively investigated during a follow-up period of up to 5 years. RESULTS: The plasma follistatin concentration was not higher in CKD stage 5 patients than in other CKD stages or controls. In CKD stage 5 patients, circulating follistatin positively correlated with age, high-sensitivity C-reactive protein (hsCRP), and IL-6; negatively correlated with HGS, serum creatinine, and BMD; and was increased in patients with PEW. In a multivariate logistic regression model, lower HGS, lower BMD, and higher hsCRP independently correlated with higher follistatin levels. In a Cox regression model, follistatin levels were not associated with all-cause mortality. CONCLUSIONS: Circulating follistatin levels were neither elevated nor predicted outcome in patients with CKD. However, increased follistatin levels occurred together with increased inflammation, reduced muscle strength, and low BMD, suggesting an involvement of a mechanism including follistatin in the uremic wasting process.
Authors: Keisuke Matsubara; Peter Stenvinkel; Abdul Rashid Qureshi; Juan Jesús Carrero; Jonas Axelsson; Olof Heimbürger; Peter Bárány; Anders Alvestrand; Bengt Lindholm; Mohamed E Suliman Journal: J Nephrol Date: 2009 Nov-Dec Impact factor: 3.902
Authors: A S Detsky; J P Baker; K O'Rourke; N Johnston; J Whitwell; R A Mendelson; K N Jeejeebhoy Journal: JPEN J Parenter Enteral Nutr Date: 1987 Sep-Oct Impact factor: 4.016
Authors: R H Khoury; Q F Wang; W F Crowley; J E Hall; A L Schneyer; T Toth; A R Midgley; P M Sluss Journal: J Clin Endocrinol Metab Date: 1995-04 Impact factor: 5.958
Authors: Simona Iezzi; Monica Di Padova; Carlo Serra; Giuseppina Caretti; Cristiano Simone; Eric Maklan; Giulia Minetti; Po Zhao; Eric P Hoffman; Pier Lorenzo Puri; Vittorio Sartorelli Journal: Dev Cell Date: 2004-05 Impact factor: 12.270
Authors: Alice Sabatino; Giuseppe Regolisti; Giuseppe Benigno; Francesca Di Mario; Carla Maria Avesani; Enrico Fiaccadori Journal: J Nephrol Date: 2021-10-07 Impact factor: 3.902
Authors: Myong-Won Seo; Sung-Woo Jung; Sung-Woo Kim; Hyun Chul Jung; Deog-Yoon Kim; Jong Kook Song Journal: Int J Environ Res Public Health Date: 2020-09-10 Impact factor: 3.390